Search results
Showing 1 to 15 of 46 results for glucose injection
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT-2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
This quality standard covers diagnosing and managing type 1 and type 2 diabetes in children and young people (under 18). It describes high-quality care in priority areas for improvement.
View quality statements for QS125Show all sections
Sections for QS125
- Quality statements
- Quality statement 1: Same-day referral and appointments
- Quality statement 2: Education and information
- Quality statement 3: Intensive insulin therapy and level 3 carbohydrate-counting education for type 1 diabetes
- Quality statement 4: Continuous glucose monitoring in type 1 diabetes
- Quality statement 5: Blood ketone monitoring in type 1 diabetes
- Quality statement 6: Access to mental health professionals with an understanding of type 1 or type 2 diabetes
- Update information
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over.
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .